Toregem BioPharma Passes AMED Stage Gate Evaluation under the “Strengthening Program for Pharmaceutical Startup Ecosystem”

Toregem BioPharma Co., Ltd. is pleased to announce that our project, “Development of a new antibody drug to treat congenital tooth agenesis,”has successfully passed the interim Stage Gate evaluation under the “Strengthening Program for Pharmaceutical Startup Ecosystem (Open Call for Drug Discovery Ventures)”administered by the Japan Agency for Medical Research and Development (AMED) in 2025.

This positive evaluation reflects the successful achievement of our Stage 1 milestones, including:
・Completion of the domestic Phase 1 clinical trial
・Conduct of a Pre-IND meeting with regulatory authorities
・Strengthening of our organizational and governance structure
・Demonstration of high feasibility and advancement of our development plan

We will continue to accelerate the development of first-in-class regenerative antibody therapeutics, striving to realize a society free from the fear of tooth loss.